All In Biotech

Drug Trial Radar · NCT02242760

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

A Phase 2, Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled Study Comparing the Efficacy, Tolerability, and Safety of SB204 Gel and Vehicle Gel Once or Twice Daily in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

213

Actual

Start

Nov 2014

Primary completion

Jun 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Novan, Inc.Industry
Sponsor type
Industry
First posted
Sep 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.

Conditions

  • Acne Vulgaris

Interventions

  • SB204 2%Drug

    Applied topically twice daily

  • SB204 4%Drug

    Applied topically daily

  • Vehicle GelDrug

    Applied topically twice and once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Inflammatory Lesion CountsTime frame: Baseline and Week 12
  2. Absolute Change in Non-inflammatory Lesion CountsTime frame: Baseline and Week 12
  3. Proportion of Success According to the Dichotomized Investigator Global Assessment [IGA] at End of TreatmentTime frame: Baseline and Week 12

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Qst acne site #1

    Hot Springs, Arkansas

  • QST Site #118

    Encinitas, California

  • QST Site #111

    San Diego, California

  • QST Site #113

    San Diego, California

  • QST Site #119

    Santa Monica, California

  • QST Site #103

    Boca Raton, Florida

  • QST Site # 110

    Pinellas Park, Florida

  • QST Site # 116

    Newnan, Georgia

  • QST Site #117

    Louisville, Kentucky

  • QST Site #112

    Detroit, Michigan

  • QST Site #120

    Warren, Michigan

  • QST Site # 121

    Minneapolis, Minnesota

  • QST Site #107

    New York, New York

  • QST Site #108

    Rochester, New York

  • QST Site #109

    Rochester, New York

  • QST Site #104

    Stony Brook, New York

  • QST Site # 102

    San Antonio, Texas

  • QST Site #106

    Salt Lake City, Utah

  • QST #105

    Lynchburg, Virginia

  • QST Site #114

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.